Sign in

Majmundar Laboratory

@majmundarlab.bsky.social
42 followers 176 following 26 posts

Kidney Genetics Laboratory @bostonchildrens.bsky.social @harvardmed.bsky.social majmundarlab.com Driven to discover, model and treat genetic kidney diseases.

PostsRepliesMedia
Majmundar Laboratory @majmundarlab.bsky.social · 03/09/2026
Integrating genetic testing into kidney care starts with helping nephrologists build fluency in genetics. Recently gave two seminars at World Kidney Academy Genetic Kidney Disease Masterclass: core genetic concepts for nephrologists, and genetic testing in CKD of unclear etiology.
110 0
Majmundar Laboratory @majmundarlab.bsky.social · 02/09/2026
Genetic testing in nephrology has exploded, creating opportunities but also challenges for providers and families. We started @bostonchildrens.bsky.social Kidney Genetics Clinic to address gaps in counseling and delivery. See our outcomes in Kidney360 @asnpublications.bsky.social: bit.ly/3SIhCF6
bit.ly
Real-World Outcomes of a Pediatric Kidney... : Kidney360
Background:Despite the growing role of genetic testing in pediatric kidney disease, translating genomic findings into clinical care remains...
110 0
Majmundar Laboratory @majmundarlab.bsky.social · 10/07/2026
Honored to have given Grand Rounds at Boston Children's Hospital on clinical implementation of genetic testing and genetic mechanisms of glomerular disease. Excited to work at the intersection of rare disease genomics and pediatric kidney care. @bostonchildrens.bsky.social @harvardmed.bsky.social
010 0
Majmundar Laboratory @majmundarlab.bsky.social · 20/05/2026
Thankful to contribute to the @kdigo.org FSGS Summit in New Orleans led by Co-Chairs Brad Rovin and Laura Mariani to consider genetic testing and its impacts in FSGS alongside colleagues Ana Onuchic-Whitford, John Sim, Nina Mann, Johannes Schlondorff.
021 0
Majmundar Laboratory @majmundarlab.bsky.social · 20/05/2026
Appreciate the opportunity to speak on variants of uncertain significance (VUS) in kidney genetic testing @kidneycon.bsky.social 2026 in Little Rock. Thank you to @uamshealth.bsky.social, @arkanalabs.bsky.social, Drs. John Arthur and Shree Sharma.
111 0
Majmundar Laboratory @majmundarlab.bsky.social · 15/03/2026
🔬 #PostdocOpening @majmundarlab.bsky.social @bostonchildrens.bsky.social @harvardmed.bsky.social Come join us to study genetic kidney disease in kids — NS/FSGS, podocytes, cell biology, disease modeling. Looking for a driven PhD or MD with cell bio, mouse, iPSC experience. bit.ly/4sHFXaj
bit.ly
000 0
Majmundar Laboratory @majmundarlab.bsky.social · 14/03/2026
Extremely proud of our MS thesis students presenting oral talks and posters on our lab's work at the Joint 44th PNRC Mtg & 52nd Miami Peds Neph Seminar! 🧬 🫘 @majmundarlab.bsky.social @bostonchildrens.bsky.social @harvardmed.bsky.social
100 0
Majmundar Laboratory @majmundarlab.bsky.social · 27/02/2026
Congratulations to Florian Buerger, Nils Mertens, Camille Nicolas Frank, Friedhelm Hildebrandt, and co. on our paper out in @kireports.bsky.social! Happy I could make a small contribution to this in-depth study. kireports.org/article/S246... @bostonchildrens.bsky.social @harvardmed.bsky.social
kireports.org
NPHS2 Revisited through 208 Cases and Podocin Complex Modeling
Steroid-resistant nephrotic syndrome (SRNS) is the leading cause of chronic glomerular disease in individuals under 25 years of age. Biallelic variants in NPHS2, encoding podocin, are the most common ...
142 0
Majmundar Laboratory @majmundarlab.bsky.social · 31/01/2026
Sharing a exciting study by Howard Trachtman and colleagues in Lancet demonstrating efficacy of a targeted therapy for genetic FSGS. Exciting development and blueprint for tackling other genetic kidney diseases. thelancet.com/journals/lancet/article/PIIS0140-6736(25)02255-X/abstract?rss=yes
thelancet.com
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials...
010 0
Reposted by Majmundar Laboratory
MIT Koch Institute @mitkochinstitute.bsky.social · 12/12/2025
Predicting better lipids: In a cover-winning @natbiotech.nature.com paper, the Anderson & Langer Labs screened 1.6M lipids in silico to speed up successful designs for mRNA delivery to lungs. www.nature.com/articles/s41...
Pink and green illustration of lipid nanoparticles against a blue background - the there is text that says Nature Biotechnology on top and the bottom has text that reads Lung delivery using AI-designed lipid nanoparticles
032 0
Majmundar Laboratory @majmundarlab.bsky.social · 11/12/2025
Genes regulate kidney stones. In our recent editorial, Ken Saida and I review the evolving landscape of Mendelian genetics in KSD and discuss findings from a large cohort analysis in cJASN: doi.org/10.2215/CJN.... @harvardmed.bsky.social @bostonchildrens.bsky.social
doi.org
041 0
Majmundar Laboratory @majmundarlab.bsky.social · 11/12/2025
In our new @natcomms.nature.com study, we show that intergenic splicing of the NS disease gene/actin regulator NOS1AP is essential for kidney filter function via transcriptomic, proteomic, human genetic & mouse model studies. @harvardmed.bsky.social @bostonchildrens.bsky.social t.co/2xegr1OUlm
t.co
https://www.nature.com/articles/s41467-025-65663-6
130 0